Oscient Gets Factive Price Reduction From LG Life Sciences For European Distribution
This article was originally published in The Pink Sheet Daily
Oscient indicates the agreement could help facilitate a European partnership for the antibiotic.
You may also be interested in...
FDA accepts Oscient’s submission as a “complete response” to a Sept. 21 “approvable” letter for the antibiotic.
Panel votes 11-2 that Oscient has not demonstrated gemifloxacin is safe and efficacious in treatment of acute bacterial sinusitis.
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.